Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.

@article{BodetMilin2016ImmunoPETUA,
  title={Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.},
  author={Caroline Bodet-Milin and Alain Faivre-Chauvet and Thomas Carlier and Aurore Rauscher and Mickael Bourgeois and Evelyne Cerato and Vincent Rohmer and Olivier F Couturier and Delphine Drui and David M. Goldenberg and Robert M Sharkey and Jacques Barbet and Françoise Kraeber-Bod{\'e}r{\'e}},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2016},
  volume={57 10},
  pages={1505-1511}
}
Earlier clinical studies reported a high sensitivity of pretargeted immunoscintigraphy using murine or chimeric anticarcinoembryonic antigen (CEA) bispecific antibody (BsMAb) and peptides labeled with 111In or 131I in medullary thyroid carcinoma (MTC). Preclinical studies showed that new-generation humanized recombinant anti-CEA × antihistamine-succinyl-glycine (HSG) trivalent BsMAb TF2 and radiolabeled HSG peptide (IMP288) present good features for PET. This study aimed at optimizing molar… CONTINUE READING
Highly Cited
This paper has 30 citations. REVIEW CITATIONS